TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International, Open, Randomized, Controlled Study to Evaluate the Efficacy of Combining Prophylactic Curosurf® With Early Nasal CPAP Versus Early Nasal CPAP Alone in Very Preterm Infants at Risk of Respiratory Distress Syndrome
Brief Summary: The primary objective of this study is to compare two methods of post-delivery stabilization and subsequent early respiratory care for reducing the need for MV and related secondary complications, such as BPD, in premature babies at high risk of RDS:

1. Early stabilization on nCPAP
2. Intubation, prophylactic surfactant (Curosurf®) administration shortly after delivery, and rapid extubation to nCPAP.

The data obtained from this comparison will be applied to test the hypothesis that preterm neonates at risk of RDS who are treated with prophylactic surfactant + nCPAP show less need for MV when compared to infants who receive nCPAP alone.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Very early surfactant and bubble NCPAP | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: bubble NCPAP | Intervention Type: OTHER; Name: Very early surfactant and bubble NCPAP; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: bubble NCPAP; Assigned to Arm(s): 2
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Poractant alfa (Curosurf®) | Intervention Type: DRUG; Name: Poractant alfa (Curosurf®); Assigned to Arm(s): 2
C: Intervention Type: DEVICE; Name: Early Bubble CPAP; Assigned to Arm(s): N/A
D: Arm Label: PS Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: PS Group | Arm Label: NCPAP Group; Type: EXPERIMENTAL; Interventions: Device: NCPAP Group | Arm Label: ISX Group; Type: EXPERIMENTAL; Interventions: Drug: ISX Group | Intervention Type: DRUG; Name: PS Group; Assigned to Arm(s): PS Group | Intervention Type: DEVICE; Name: NCPAP Group; Assigned to Arm(s): NCPAP Group | Intervention Type: DRUG; Name: ISX Group; Assigned to Arm(s): ISX Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Coccinia Cordifolia Extract in Improving Blood Glucose Levels of Newly Diagnosed Diabetic Patients
Brief Summary: The purpose of the study was to evaluate the effectiveness of Coccinia Cordifolia (synonym Coccinia indica) on the blood glucose levels of newly detected type 2 diabetic patients requiring only behavioral or lifestyle intervention. The hypothesis of the study is that there will be significant decrease in the blood glucose levels after a period of 90 days in the diabetic patients who consumed the coccinia extract.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cinnamon or placebo 500 mg capsule twice daily | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cinnamon or placebo 500 mg capsule twice daily | Intervention Type: DRUG; Name: Cinnamon or placebo 500 mg capsule twice daily; Assigned to Arm(s): 1, 2
B: Intervention Type: DRUG; Name: Coccinia Cordifolia (herbal extract); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: cinnamon; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: human insulin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adjuvant Low-dose Interleukin-2 (IL2) Plus Interferone-alpha (IFN) in Operable Renal Cell Cancer (RCC). Phase III, Randomized, Multicenter Trial of the Italian Oncology Group for Clinical Research (GOIRC).
Brief Summary: The aim of this study is to compare the efficacy (in terms of event-free survival and overall survival) of an adjuvant therapy with IFN-alpha plus low-dose of IL2 vs a wait-and-see program in patient with radically operated renal cell carcinoma.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon Alfa | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: CCI-779 | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Interferon Alfa and CCI-779 | Intervention Type: DRUG; Name: Interferon Alfa; Assigned to Arm(s): A | Intervention Type: DRUG; Name: CCI-779; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Interferon Alfa and CCI-779; Assigned to Arm(s): C
B: Arm Label: Arm 1: nivolumab - 0.3 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: nivolumab | Arm Label: Arm 2: nivolumab - 2.0 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: nivolumab | Arm Label: Arm 3: nivolumab - 10.0 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: nivolumab | Intervention Type: BIOLOGICAL; Name: nivolumab; Assigned to Arm(s): Arm 1: nivolumab - 0.3 mg/kg | Intervention Type: BIOLOGICAL; Name: nivolumab; Assigned to Arm(s): Arm 2: nivolumab - 2.0 mg/kg | Intervention Type: BIOLOGICAL; Name: nivolumab; Assigned to Arm(s): Arm 3: nivolumab - 10.0 mg/kg
C: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Sorafenib, Drug: AMG 386 placebo IV | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Sorafenib | Arm Label: Arm C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib, Drug: AMG 386 placebo IV | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): Arm A, Arm B, Arm C | Intervention Type: DRUG; Name: AMG 386 placebo IV; Assigned to Arm(s): Arm A, Arm C
D: Arm Label: A-immunotherapy; Type: EXPERIMENTAL; Interventions: Drug: Interferon Alfa-2a, Drug: Interleukin-2 | Arm Label: B-follow-up; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Interferon Alfa-2a; Assigned to Arm(s): A-immunotherapy | Intervention Type: DRUG; Name: Interleukin-2; Assigned to Arm(s): A-immunotherapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Naltrexone and Varenicline: Weight Gain and Tolerability in Smokers
Brief Summary: The purpose of this study is to determine whether the combination of naltrexone (Depade) and varenicline (Chantix) minimizes post-smoking cessation weight gain and how well the combination is tolerated.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone, Drug: Varenicline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1, 2
B: Arm Label: Scheduled Gradual Reduction + Varenicline; Type: EXPERIMENTAL; Interventions: Other: Scheduled Gradual Reduction + Varenicline | Arm Label: Scheduled Gradual Reduction + Placebo Drug; Type: EXPERIMENTAL; Interventions: Other: Scheduled Gradual Reduction + Placebo Drug | Arm Label: Basic Advice + Varenicline; Type: EXPERIMENTAL; Interventions: Other: Basic Advice + Varenicline | Arm Label: Basic Advice + Placebo Drug; Type: PLACEBO_COMPARATOR; Interventions: Other: Basic Advice + Placebo Drug | Intervention Type: OTHER; Name: Scheduled Gradual Reduction + Varenicline; Assigned to Arm(s): Scheduled Gradual Reduction + Varenicline | Intervention Type: OTHER; Name: Scheduled Gradual Reduction + Placebo Drug; Assigned to Arm(s): Scheduled Gradual Reduction + Placebo Drug | Intervention Type: OTHER; Name: Basic Advice + Varenicline; Assigned to Arm(s): Basic Advice + Varenicline | Intervention Type: OTHER; Name: Basic Advice + Placebo Drug; Assigned to Arm(s): Basic Advice + Placebo Drug
C: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Arm II; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm III; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine | Intervention Type: DRUG; Name: nicotine; Assigned to Arm(s): Arm III | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II
D: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Naltrexone and Varenicline: Weight Gain and Tolerability in Smokers
Brief Summary: The purpose of this study is to determine whether the combination of naltrexone (Depade) and varenicline (Chantix) minimizes post-smoking cessation weight gain and how well the combination is tolerated.


Options:
A: Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A
B: Arm Label: Varenicline + Active Tailored Dose; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Varenicline + Placebo Tailored Dose; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Tailored Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Varenicline + Placebo Tailored Dose | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Tailored Dose, Varenicline + Placebo Tailored Dose
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Transdermal Nicotine Patch; Type: EXPERIMENTAL; Interventions: Drug: Transdermal Nicotine Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Transdermal Nicotine Patch; Assigned to Arm(s): Transdermal Nicotine Patch
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone, Drug: Varenicline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1, 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Naltrexone and Varenicline: Weight Gain and Tolerability in Smokers
Brief Summary: The purpose of this study is to determine whether the combination of naltrexone (Depade) and varenicline (Chantix) minimizes post-smoking cessation weight gain and how well the combination is tolerated.


Options:
A: Arm Label: Bupropion; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Behavioral: Smoking Cessation Counseling | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Smoking Cessation Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Smoking Cessation Counseling | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Smoking Cessation Counseling; Assigned to Arm(s): Bupropion, Placebo, Varenicline
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Behavioral group smoking cessation treatment | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Behavioral group smoking cessation treatment, Drug: Placebo | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Behavioral group smoking cessation treatment; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone, Drug: Varenicline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1, 2
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Naltrexone and Varenicline: Weight Gain and Tolerability in Smokers
Brief Summary: The purpose of this study is to determine whether the combination of naltrexone (Depade) and varenicline (Chantix) minimizes post-smoking cessation weight gain and how well the combination is tolerated.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone, Drug: Varenicline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1, 2
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Naltrexone and Varenicline: Weight Gain and Tolerability in Smokers
Brief Summary: The purpose of this study is to determine whether the combination of naltrexone (Depade) and varenicline (Chantix) minimizes post-smoking cessation weight gain and how well the combination is tolerated.


Options:
A: Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Treatment Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline (CP-526,555) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo Arm | Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): Treatment Arm
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone, Drug: Varenicline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1, 2
C: Arm Label: Varenicline & nicotine patches; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Drug: Nicotine patches | Arm Label: Varenicline & placebo patches; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: Placebo (nicotine patches) | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline & nicotine patches, Varenicline & placebo patches | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Varenicline & nicotine patches | Intervention Type: DRUG; Name: Placebo (nicotine patches); Assigned to Arm(s): Varenicline & placebo patches
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Pharmacist-delivered group program for smoking cessation | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Brief standard care session for smoking cessation delivered over the telephone | Intervention Type: OTHER; Name: Pharmacist-delivered group program for smoking cessation; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Brief standard care session for smoking cessation delivered over the telephone; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Telemonitoring in Patients With Heart Failure
Brief Summary: The purpose of this study is to investigate if telemonitoring results in a decrease in hospital admissions, with equal quality of care defined as mortality, quality of life and unplanned visits with caregivers. Telemonitoring is expected to be more cost-effective than usual care in patients with heart failure.


Options:
A: Arm Label: telemonitoring; Type: EXPERIMENTAL; Interventions: Device: Health Buddy system | Arm Label: usual care; Type: EXPERIMENTAL; Interventions: Device: Telemonitoring in patients with heart failure | Intervention Type: DEVICE; Name: Health Buddy system; Assigned to Arm(s): telemonitoring | Intervention Type: DEVICE; Name: Telemonitoring in patients with heart failure; Assigned to Arm(s): usual care
B: Arm Label: 1; Type: OTHER; Interventions: Drug: Insulin glulisine, Drug: Insulin glargine, Drug: Metformin | Arm Label: 2; Type: OTHER; Interventions: Drug: Insulin glulisine, Drug: Insulin glargine, Drug: Metformin | Intervention Type: DRUG; Name: Insulin glulisine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Insulin glargine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 1, 2
C: Arm Label: TELEmonitoring intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Medication Adherence Support System (MASS) | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Medication Adherence Support System (MASS); Assigned to Arm(s): TELEmonitoring intervention
D: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Transtelephonic monitoring (TTM) | Arm Label: Remote; Type: ACTIVE_COMPARATOR; Interventions: Other: Medtronic CareLink® Network | Intervention Type: OTHER; Name: Transtelephonic monitoring (TTM); Assigned to Arm(s): Control | Intervention Type: OTHER; Name: Medtronic CareLink® Network; Assigned to Arm(s): Remote

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter Evaluation of The Effectiveness of Source Control With Daily Chlorhexidine Skin Preparation in Reducing Nosocomial Infections Including MRSA and VRE
Brief Summary: To determine if daily bathing with chlorhexidine impregnated washcloths will reduce the incidence of MRSA and VRE within an Intensive Care Unit (ICU) or ward setting.


Options:
A: Arm Label: Active Screening; Type: OTHER; Interventions: Device: nucleic acid amplification of nasal swab; nasal swab culture | Arm Label: Passive Screening; Type: OTHER; Interventions: Other: Nasal swab culture | Intervention Type: DEVICE; Name: nucleic acid amplification of nasal swab; nasal swab culture; Assigned to Arm(s): Active Screening | Intervention Type: OTHER; Name: Nasal swab culture; Assigned to Arm(s): Passive Screening
B: Intervention Type: PROCEDURE; Name: Bathing with Chlorhexidine Impregnated Washcloths; Assigned to Arm(s): N/A
C: Arm Label: Intervention Arm; Type: N/A; Interventions: N/A | Arm Label: Non-intervention - Usual Standard of Care; Type: N/A; Interventions: N/A
D: Arm Label: White coat group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Uniform group; Type: EXPERIMENTAL; Interventions: Other: Physician uniform | Intervention Type: OTHER; Name: Physician uniform; Assigned to Arm(s): Uniform group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter Evaluation of The Effectiveness of Source Control With Daily Chlorhexidine Skin Preparation in Reducing Nosocomial Infections Including MRSA and VRE
Brief Summary: To determine if daily bathing with chlorhexidine impregnated washcloths will reduce the incidence of MRSA and VRE within an Intensive Care Unit (ICU) or ward setting.


Options:
A: Arm Label: chlorhexidine gluconate (CHG); Type: EXPERIMENTAL; Interventions: Drug: 2% chlorhexidine gluconate impregnated cloth | Arm Label: Soap & Water; Type: ACTIVE_COMPARATOR; Interventions: Other: Daily bathing with Bar soap | Intervention Type: DRUG; Name: 2% chlorhexidine gluconate impregnated cloth; Assigned to Arm(s): chlorhexidine gluconate (CHG) | Intervention Type: OTHER; Name: Daily bathing with Bar soap; Assigned to Arm(s): Soap & Water
B: Arm Label: Soap bathing; Type: PLACEBO_COMPARATOR; Interventions: Drug: Soap | Arm Label: 2% chlorhexidine wipes; Type: EXPERIMENTAL; Interventions: Drug: 2% chlorhexidine wipe | Intervention Type: DRUG; Name: 2% chlorhexidine wipe; Assigned to Arm(s): 2% chlorhexidine wipes | Intervention Type: DRUG; Name: Soap; Assigned to Arm(s): Soap bathing
C: Intervention Type: PROCEDURE; Name: Reinforced isolation + Muciprocine; Assigned to Arm(s): N/A
D: Intervention Type: PROCEDURE; Name: Bathing with Chlorhexidine Impregnated Washcloths; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open Label Study Evaluating the Effect on Renal Function of Intravenous Bonviva Given by Injection or Infusion, Compared With Oral Alendronate, in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
Brief Summary: This 3 arm study will evaluate renal safety after administration of an intravenous (iv) injection or infusion of Bonviva, compared to oral alendronate, in patients with postmenopausal osteoporosis, at increased risk of renal disease. Patients will be randomized to receive Bonviva 3mg intravenous (iv) by a) injection or b) infusion once every 3 months, or alendronate 70mg per oral (po) weekly. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.


Options:
A: Arm Label: Control, low turnover; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment, low turnover; Type: EXPERIMENTAL; Interventions: Drug: Teriparatide, Drug: Cinacalcet | Arm Label: Control, high turnover; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment, high turnover; Type: EXPERIMENTAL; Interventions: Drug: Alendronate | Intervention Type: DRUG; Name: Alendronate; Assigned to Arm(s): Treatment, high turnover | Intervention Type: DRUG; Name: Teriparatide; Assigned to Arm(s): Treatment, low turnover | Intervention Type: DRUG; Name: Cinacalcet; Assigned to Arm(s): Treatment, low turnover
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Alendronate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Alendronate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: ibandronate [Bonviva/Boniva] | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: ibandronate [Bonviva/Boniva] | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Alendronate | Intervention Type: DRUG; Name: ibandronate [Bonviva/Boniva]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: ibandronate [Bonviva/Boniva]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Alendronate; Assigned to Arm(s): 3
D: Intervention Type: DRUG; Name: alendronate; Assigned to Arm(s): N/A

Answer: C